KINE-501E

KINE-501E is an investigational peptide-based therapeutic developed by Kine Science for the treatment of Multiple Sclerosis (MS). It belongs to a platform of 'Kine-Peptides' designed to modulate the activity of microglial cells, which are the primary immune cells of the central nervous system. In neurodegenerative and neuroinflammatory conditions like MS, microglial activation can lead to the release of pro-inflammatory cytokines and contribute to demyelination and neuronal damage. KINE-501E aims to regulate microglial activation, shifting the immune environment toward a neuroprotective state and suppressing neuroinflammation. The asset is currently in the discovery or early preclinical stage of development, with potential utility in other neurodegenerative diseases such as Alzheimer's and Parkinson's.